Cell-Derived Xenografts

Cell line-derived xenograft (CDX) models are a cornerstone of preclinical oncology.

Built from well-characterised human tumour cell lines implanted into immunodeficient hosts, they offer reproducible and cost-effective tools for evaluating anti-tumour efficacy across a wide range of cancer indications.

At Antineo, we have almost 200 cell lines models most of which have been tested for their capacity to grow as subcutaneous xenografts in immunodeficient mice. Our preferred strain is SCID CB17, as they allow an efficient but not too aggressive tumour uptake while retaining a residual immune system suitable for evaluating therapeutic antibodies.

We are also approved to implant in athymic Nude, NOD-SCID, and CEIA NOG mice, with additional strains available on request within a few weeks.

Why CDX models?

  • Reproducibility and throughput

CDX models rely on established and well-characterised human cell lines, providing consistent tumour growth rates and a stable genetic background across experiments. This makes them particularly suited to comparative efficacy studies and dose-response evaluations.

  • Broad indication coverage

Our collection covers over 20 cancer types. It spans both haematological malignancies and solid tumours, including breast, colorectal, lung, ovarian, pancreatic, and melanoma. This broad range enables compound profiling across clinically relevant indications.

  • Flexible implantation and monitoring

Models are available for subcutaneous, orthotopic, or intravenous implantation. Bioluminescent variants enable non-invasive tumour monitoring via in vivo imaging (IVIS), and many models have been tested with standard-of-care agents to provide a benchmarking reference.

Liquid tumours in Xenograft models

In vitro cultivated human haematological cell lines are implanted into immunodeficient mice to create Cell line-Derived Xenograft (CDX) models, which are used to assess the effectiveness of potential cancer treatments in a controlled in vivo environment.

At Antineo, liquid CDX models are available for subcutaneous or intravenous implantation. They can be monitored via bioluminescent imaging, routine blood collection, and flow-cytometry detection of specific markers.
Our collection covers a wide range of haematological malignancies, from acute leukemias to B- and T-cell lymphomas and myeloma.

Acute Lymphoblastoid Leukemia, B cells
  • RS4;11 (View PDF)
  • 697 (On request)

Acute Lymphoblastoid Leukemia, B cells
  • CCRF-CEM (View PDF)
  • JM (View PDF)
  • Jurkat (On request)
  • Molt-4 (On request)
  • Reh (On request)

Acute Myeloid Leukemia

Chronic Lymphocitic Leuke mia, B cells

  • MEC1 (View PDF)
  • BV-173 (On request)

Burkitt's Lymphoma
  • Daudi (View PDF)
  • Ramos (View PDF)
  • Raji (View PDF)
  • EB2 (On request)
  • NaMalwa (On request)

Diffuse Large B Cells Lymphoma

Follicular Lymphoma
  • RL (View PDF)
  • DOHH2 (On request)

Malignant histiocytosis

Mantle Cells Lymphoma

Myeloma
  • AMO1 (View PDF)
  • MM.1S (View PDF)
  • RPMI8226 (View PDF)
  • U266 (View PDF)
  • OPM-2 (On request)
  • LP1 (On request)
  • NCI-N929 (On request)

Cutaneous T lymphoma

  • Myla (View PDF)
  • HUT-78 (On request)

Solid tumours in Xenograft models

 

Human solid tumour cell lines are implanted subcutaneously or orthotopically into immunocompromised mice, enabling the study of tumour growth and response to treatment without graft rejection. Antineo’s solid CDX models cover a wide range of indications and implantation routes, including orthotopic, subcutaneous, and metastatic configurations.

 

Each model in our collection has been established and verified in-house. Many have been tested with standard-of-care agents, providing a reliable efficacy benchmark for your compound. Our scientific team can assist in selecting the most appropriate model for your mechanism of action, or design a multi-indication profiling strategy across our panel.

Bladder cancer
  • ScaBER (On request)
  • 5637 (On request)
  • T24 (On request)
  • J82 (On request)
  • RT4 (On request)

Breast cancer
  • MCF7 (View PDF)
  • HCC1806 (View PDF)
  • BT474 (View PDF)
  • DU4475 (View PDF)
  • MDA-MB-157(On request)
  • MDA-MB-175 (On request)
  • MDA-MB-231 (View PDF)
  • MDA-MB-361(On request)
  • MDA-MB-436 (On request)
  • MDA-MB-453 (On request)
  • MDA-MB-468 (On request)
  • BT549 (On request)
  • JIMT-1 (On request)
  • SK-BR-3 (On request)
  • CAMA-1 (On request)
  • T47D (On request)
  • ZR-75-1 (On request)

Colorectal cancer
  • HCT 116 (View PDF)
  • HT-29 (View PDF)
  • Isreco-1 (View PDF)
  • SW620 (View PDF)
  • COLO 320 (On request)
  • Isreco-3 (On request)
  • SW403 (On request)

Esophagus cancer

Gastric cancer
  • SNU-5 (View PDF)
  • Hs746T (View PDF)
  • NCI-N87 (On request)

Glioblastoma
  • U251 (View PDF)
  • T98G (On request)
  • U-87 (View PDF)
  • ADF (On request)

Head and Neck cancer
  • FaDu (View PDF)
  • HN097 (View PDF)
  • CAL-27 (View PDF)
  • BICR 18 (View PDF)
  • BICR 22 (On request)
  • BICR 56 (On request)
  • DETROIT562 (On request)
  • H357 (On request)

Hepatic cancer
  • HepaRG (On request)
  • HepG2 (On request)

Lung cancer
  • A549 (View PDF)
  • NCI-H292 (View PDF)
  • NCI-H596 (On request)
  • NCI-H1703 (On request)
  • NCI-H1975 (View PDF)
  • HCC-78 (On request)
  • HCC95 (On request)
  • HCC827 (On request)
  • SK-MES-1 (On request)
  • MSTO-211H (Pleural Biphasic Mesothelioma) (On request)
  • ISTMes2 (Pleural Epithelioid Mesothelioma) (On request)

Melanoma
  • A2058 (View PDF)
  • MeWo (View PDF)
  • MEL Juso (View PDF)
  • Colo 829 (View PDF)
  • SK-MEL-2 (On request)
  • SK-MEL-5 (View PDF)
  • SK-MEL-24 (On request)
  • Malme-3 (On request)
  • A-375 (On request)
  • HMCB (On request)
  • Hs940T (On request)
  • IGR39 (On request)
  • C8161 (View PDF)

Neuroblastoma cancer
  • SH-SY5Y (On request)

Ovarian cancer
  • A2780 (View PDF)
  • SK-0V-3 (View PDF)
  • OV-90 (View PDF)
  • OV-CAR-3 (View PDF)
  • PA-1 (View PDF)
  • Cov434 (On request)
  • AG6000 (On request)
  • TOV-112D (On request)

Pancreatic cancer

Prostate cancer
  • DU145 (View PDF)
  • PC3 (View PDF)
  • LNCaP (On request)

Sarcoma

  • SK-LMS-1 (View PDF)
  • A-673 (On request)
  • MES-SA (On request)

Contact our Team to learn more

Contact